Clinical Trial Update: Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

View source ↗

Summary

A completed clinical trial evaluating how Oncotype DX reclassifies recurrence risk in breast cancer patients with uncertain tumor biology.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fondazione Sandro Pitigliani | Conditions: Breast Cancer | Status: COMPLETED